The type of malignancy which seems to be more closely associated with insulin therapy in patients with type 2 diabetes is pancreatic cancer; the reported incidence in insulin-treated individuals is two- to five-fold higher than in other patients with diabetes [36, 38]. This evidence concerns the gene INS and pancreatic neoplasm.